Follows people with neurologic conditions using the EXOPULSE suit over time
Records outcomes of people with neurologic conditions who use the EXOPULSE suit.
Plain-language title generated from the registry record
Registry title: The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes
Key facts
- Where
- Bergshamra, SwedenSee the site
Where in Sweden
- Ottobock Care SverigeBergshamra, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Otto Bock Healthcare Products GmbH
- Trial code
- NCT05901259
- Record updated
- 14 September 2026
- Original description
The objective is to explore the potential short and long-term impact of the EXOPULSE Mollii Suit and EXOPULSE Suit on subjects with CP, MS, stroke, fibromyalgia or other neurologic disorders which may cause such types of symptoms, and to identify high responders among the sub-categories of the diagnoses. The primary endpoint will be improvements in the Berg/Pediatric Balance Scale (BBS/PBS) as a measurement of balance and risk of falls.Read full original descriptionShow less
The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes
The objective is to explore the potential short and long-term impact of the EXOPULSE Mollii Suit and EXOPULSE Suit on subjects with CP, MS, stroke, fibromyalgia or other neurologic disorders which may cause such types of symptoms, and to identify high responders among the sub-categories of the diagnoses. The primary endpoint will be improvements in the Berg/Pediatric Balance Scale (BBS/PBS) as a measurement of balance and risk of falls.
Inclusion: Diagnosed with CP, MS, stroke, fibromyalgia or other neurologic disorder that may cause such type of symptoms; Diagnosed >6 months prior to inclusion in case of MS or stroke as well as >1 month prior to inclusion in the case of fibromyalgia; Give written informed consent; Cognitively able to understand and follow verbal and/or written instructions; A minimum age of 2 years.
Exclusion: Being introduced to any new medication affecting the neuromuscular activity during the study period; Using botulinum toxin <3 month before or during the study period; Any of the contraindications listed in the instructions for use of the EXOPULSE Mollii Suit or EXOPULSE Suit; Subjects <100 cm and <13 kg; Subjects >205 cm and >115 kg.